Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
beta blocker |
| gptkbp:approvedBy |
1982
|
| gptkbp:ATCCode |
C07AB08
|
| gptkbp:CASNumber |
56980-19-1
|
| gptkbp:contraindication |
asthma
severe bradycardia cardiogenic shock |
| gptkbp:developedBy |
Laboratoires Servier
|
| gptkbp:eliminationHalfLife |
5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C20H33N3O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
celiprolol
|
| gptkbp:IUPACName |
(RS)-1-[4-[2-(3-acetyl-2-hydroxy-5-(2-methylpropyl)phenyl)ethyl]piperazin-1-yl]ethanone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta-1 adrenergic receptor antagonist
partial beta-2 agonist |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
C (US) |
| gptkbp:proteinBinding |
25%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue bradycardia gastrointestinal disturbance |
| gptkbp:usedFor |
hypertension
angina pectoris |
| gptkbp:bfsParent |
gptkb:vascular_Ehlers-Danlos_syndrome
|
| gptkbp:bfsLayer |
7
|